Chara Papadaki

1.3k total citations
53 papers, 1.0k citations indexed

About

Chara Papadaki is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Chara Papadaki has authored 53 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 25 papers in Oncology and 25 papers in Cancer Research. Recurrent topics in Chara Papadaki's work include Lung Cancer Treatments and Mutations (14 papers), MicroRNA in disease regulation (13 papers) and Circular RNAs in diseases (12 papers). Chara Papadaki is often cited by papers focused on Lung Cancer Treatments and Mutations (14 papers), MicroRNA in disease regulation (13 papers) and Circular RNAs in diseases (12 papers). Chara Papadaki collaborates with scholars based in Greece, United States and Sweden. Chara Papadaki's co-authors include John Souglakos, Dimitriοs Mavroudis, Vassilis Georgoulias, Maria Trypaki, Sofia Agelaki, Maria Sfakianaki, Dimitris Mavroudis, Efstathios N. Stathopoulos, Anastasios Koutsopoulos and Eleni Lagoudaki and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Chara Papadaki

51 papers receiving 1.0k citations

Peers

Countries citing papers authored by Chara Papadaki

Since Specialization

Citations

This map shows the geographic impact of Chara Papadaki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chara Papadaki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chara Papadaki more than expected).

Fields of papers citing papers by Chara Papadaki

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chara Papadaki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chara Papadaki. The network helps show where Chara Papadaki may publish in the future.

Co-authorship network of co-authors of Chara Papadaki

This figure shows the co-authorship network connecting the top 25 collaborators of Chara Papadaki. A scholar is included among the top collaborators of Chara Papadaki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chara Papadaki. Chara Papadaki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	MicroRNA Expression Analysis and Biological Pathways in Chemoresistant Non-Small Cell Lung Cancer 2025 ·Cancers ·Chara Papadaki, (unknown), Aristeidis E. Boukouris, (unknown), Maria Markaki, Eleni Lagoudaki, Anastasios Koutsopoulos, Ioannis Tsamardinos, Dimitrios Mavroudis, Sofia Agelaki	0
2	Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors 2023 ·PLoS ONE ·Dimitrios Makrakis, Konstantinos Rounis, (unknown), (unknown), Nikolaos Galanakis, (unknown), Simon Ekman, Chara Papadaki, (unknown), Meropi Kontogianni, Ioannis Gioulbasanis, Dimitris Mavroudis, Sofia Agelaki	11
3	MicroRNAs Regulating Tumor Immune Response in the Prediction of the Outcome in Patients With Breast Cancer 2021 ·Frontiers in Molecular Biosciences ·(unknown), Chara Papadaki, (unknown), (unknown), (unknown), (unknown), Dimitriοs Mavroudis, Sofia Agelaki	17
4	1299P Effect of fat tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors 2021 ·Annals of Oncology ·Konstantinos Rounis, Dimitrios Makrakis, (unknown), (unknown), Nikolaos Galanakis, Georgios Tsakonas, Chara Papadaki, (unknown), Meropi Kontogianni, Ioannis Gioulbasanis, Dimitriοs Mavroudis, Sofia Agelaki	0
5	Cancer cachexia syndrome and clinical outcome in patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors: results from a prospective, observational study 2021 ·Translational Lung Cancer Research ·Konstantinos Rounis, Dimitrios Makrakis, (unknown), (unknown), Nikolaos Galanakis, Chara Papadaki, (unknown), Lambros Vamvakas, K. Kalbakis, (unknown), Meropi Kontogianni, Ioannis Gioulbasanis, Dimitriοs Mavroudis, Sofia Agelaki	38
6	PKM2 Expression as Biomarker for Resistance to Oxaliplatin-Based Chemotherapy in Colorectal Cancer 2020 ·Cancers ·Maria Sfakianaki, Chara Papadaki, Maria Tzardi, Maria Trypaki, (unknown), Ippokratis Messaritakis, Zenia Saridaki, Elias Athanasakis, Dimitriοs Mavroudis, John Tsiaoussis, Nikolaos Gouvas, John Souglakos	20
7	Correlation of PKM2 and CD44 Protein Expression with Poor Prognosis in Platinum-Treated Epithelial Ovarian Cancer: A Retrospective Study 2020 ·Cancers ·Chara Papadaki, (unknown), Eleni Lagoudaki, (unknown), Despo Ierodiakonou, (unknown), Ippokratis Messaritakis, Maria Trypaki, (unknown), Maria Sfakianaki, A. Kalykaki, Dimitriοs Mavroudis, Maria Tzardi, John Souglakos	21
8	299P MicroRNAs related to immune response as markers in the prognosis of metastatic breast cancer 2020 ·Annals of Oncology ·Sofia Agelaki, Chara Papadaki, (unknown), (unknown), (unknown), (unknown), K. Kalbakis, D. Mavroudis	1
9	Messenger-RNA Expression of Five Gemcitabine Sensitivity-related Genes Predicting Outcome in Advanced-stage Non-small Cell Lung Cancer 2020 ·Anticancer Research ·Georgios Ioannidis, Chara Papadaki, Eleni Lagoudaki, Maria Tzardi, Maria Trypaki, Efstathios N. Stathopoulos, Dimitriοs Mavroudis, V. Georgoulias, John Souglakos	1
10	PKM2 expression as biomarker for resistance to oxaliplatin-based chemotherapy in colorectal cancer 2019 ·Annals of Oncology ·Maria Sfakianaki, Chara Papadaki, Maria Tzardi, Maria Trypaki, (unknown), Ippokratis Messaritakis, Zacharenia Saridaki, Dimitriοs Mavroudis, V. Georgoulias, John Souglakos	9
11	Circulating microRNAs in the early prediction of disease recurrence in primary breast cancer 2018 ·Breast Cancer Research ·Chara Papadaki, (unknown), Georgios Markakis, Maria Spiliotaki, (unknown), Christoforos Nikolaou, Dimitriοs Mavroudis, Sofia Agelaki	64
12	Prognostic significance of CEACAM5mRNA-positive circulating tumor cells in patients with metastatic colorectal cancer 2018 ·Cancer Chemotherapy and Pharmacology ·Ippokratis Messaritakis, Maria Sfakianaki, Chara Papadaki, (unknown), N. Vardakis, Filippos Koinis, Dora Hatzidaki, Nefeli Georgoulia, Athina Kladi, Αthanasios Kotsakis, John Souglakos, Vassilis Georgoulias	18
13	Association of BRCA1, ERCC1, RAP80, PKM2, RRM1, RRM2, TS, TSP1, and TXR1 mRNA expression levels between primary tumors and infiltrated regional lymph nodes in patients with resectable non-small cell lung cancer 2018 ·The Pharmacogenomics Journal ·(unknown), Chara Papadaki, (unknown), Eleni Lagoudaki, Jessica Menis, Anastasios Koutsopoulos, Maria Trypaki, (unknown), Maria Sfakianaki, Baktiar Hasan, E. Stathopoulos, Vassilis Georgoulias, John Souglakos	5
14	ERCC1SNPs as Potential Predictive Biomarkers in Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy 2015 ·Cancer Investigation ·Aristea Kalikaki, Alexandra Voutsina, Anastasios Koutsopoulos, Chara Papadaki, Maria Sfakianaki, (unknown), Alexandros Xyrafas, Αthanasios Kotsakis, Sofia Agelaki, John Souglakos, Dimitriοs Mavroudis, Vassilis Georgoulias	12
15	PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small-cell lung cancer 2014 ·British Journal of Cancer ·Chara Papadaki, Maria Sfakianaki, Eleni Lagoudaki, (unknown), Georgios Ioannidis, Maria Trypaki, (unknown), Alexandra Voutsina, Anastasios Koutsopoulos, Dimitriοs Mavroudis, Vassilis Georgoulias, John Souglakos	51
16	Predictive Value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPΟ-IIA, TOPOIIB and C-MYC Genes in Patients with Small Cell Lung Cancer (SCLC) Who Received First Line Therapy with Cisplatin and Etoposide 2013 ·PLoS ONE ·Niki Karachaliou, Chara Papadaki, Eleni Lagoudaki, Maria Trypaki, Maria Sfakianaki, Anastasios Koutsopoulos, Dimitris Mavroudis, Efstathios N. Stathopoulos, Vassilis Georgoulias, John Souglakos	27
17	ERCC1 and BRAC1 mRNA Expression Levels in the Primary Tumor Could Predict the Effectiveness of the Second-Line Cisplatin-Based Chemotherapy in Pretreated Patients with Metastatic Non-small Cell Lung Cancer 2012 ·Journal of Thoracic Oncology ·Chara Papadaki, Maria Sfakianaki, Georgios Ioannidis, Eleni Lagoudaki, Maria Trypaki, (unknown), Dimitris Mavroudis, Efstathios N. Stathopoulos, Vassilis Georgoulias, John Souglakos	44
18	Prognostic Significance of the Detection of Peripheral Blood CEACAM5mRNA-Positive Cells by Real-Time Polymerase Chain Reaction in Operable Colorectal Cancer 2010 ·Clinical Cancer Research ·N. Vardakis, Ippokratis Messaritakis, Chara Papadaki, (unknown), Maria Sfakianaki, Zacharenia Saridaki, Stella Apostolaki, Ioannis E. Κoutroubakis, Maria Perraki, Dora Hatzidaki, Dimitris Mavroudis, Vassilis Georgoulias, John Souglakos	22
19	The upstream regulatory region of the gene for the human homologue of the adhesion molecule TAG-1 contains elements driving neural specific expression in vivo 2003 ·Molecular Brain Research ·Myrto Denaxa, (unknown), Panayoula C. Tsiotra, Georgios C. Papadopoulos, (unknown), (unknown), Chara Papadaki, Domna Karagogeos, Joseph Papamatheakis	9
20	Regional distribution and cell type-specific expression of the mouse F3 axonal glycoprotein: A developmental study 1999 ·The Journal of Comparative Neurology ·Daniela Virgintino, (unknown), (unknown), M Bertossi, Chara Papadaki, Domna Karagogeos, Gianfranco Gennarini	39

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact